ArticleScientific reports2024
Analysis of Helicobacter pylori resistance in patients with different gastric diseases.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Antimicrobial Resistance Patterns and Predictors inMicroorganisms · 2026Article
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Upregulation of innate and adaptive immune mechanisms facilitating prevention of gastricFrontiers in immunology · 2026Article
- IMPACT OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY ON THE ESOPHAGEAL/GASTRIC MUCOSA AND HELICOBACTER PYLORI IN INDIVIDUALS WITH NEUROGENIC OROPHARYNGEAL DYSPHAGIA.Arquivos de gastroenterologia · 2026Article
- In silico evaluation of the anti Helicobacter pylori activity of selected bioactive compounds from Aloe vera.Scientific reports · 2025Article
- Prevalence of Helicobacter pylori infection in patients with upper gastrointestinal disorders using different methods in Khuzestan, Southwest Iran.Molecular biology reports · 2025Article
- Open letter: challenging the removal of key bacteria from the updated 2024 WHO Bacterial Priority Pathogen List.Microbial genomics · 2025Article
- Hidden in Plain Sight: Delayed Diagnosis of Poorly Cohesive Gastric Carcinoma in a Young Male Patient.Cureus · 2025Article
- Real Way to Target Gram-Negative Pathogens: Discovery of a NovelJournal of medicinal chemistry · 2025Article
- Antibiotic resistance ofWorld journal of gastroenterology · 2025Article
- Efficacy and safety of adjunctive Chinese herbal decoction in treatingFrontiers in medicine · 2025Article
- Optimized therapeutic potential of Sijunzi-similar formulae for chronic atrophic gastritis via Bayesian network meta-analysis.EXCLI journal · 2024Article
- Network analysis of H. pylori effect on AGS human gastric adenocarcinoma cells gene expression profile.Gastroenterology and hepatology from bed to bench · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Helicobacter pylori (H. pylori) resistance is the most important risk factor for eradication failure. However, in most regions, antibiotic resistance rates of H. pylori in patients with different types of gastric mucosal lesions are still unclear. An 8-year clinical retrospective cohort study involving 2847 patients was performed. In this study, we first summarized and compared the resistance status of H. pylori in different years, ages, sexes, and gastric diseases. The resistance profiles of amoxicillin (AMX), clarithromycin (CLR), levofloxacin (LVX) and furazolidone (FR) and their changing trends in the clinic were described. Then, multiple antibiotic resistance in different gastric diseases and years were described and compared. The relationship between proton pump inhibitor (PPI) medication history and antibiotic resistance in H. pylori was also explored. Finally, an antibiotic resistance risk model was constructed for clinical resistance risk prediction. The overall resistance rates of AMX, CLR, LVX and FR in gastric diseases were 8.18%, 38.11%, 43.98%, and 13.73%, respectively. The mono resistance, double resistance, triple resistance, and quadruple resistance rates were 30.17%, 25.96%, 6.46%, and 0.63%, respectively. Compared with the period from 2014 to 2016, the rates of mono-resistance and multiple resistance all showed relatively downward trends in the past 5 years. Factors including age, sex, type of gastric lesions and recent PPI treatment history are associated with the antibiotic resistance rate of H. pylori. Atrophic gastritis is an important clinical feature of high-risk antibiotic resistance in H. pylori-infected patients. Patients with atrophic gastritis have higher risk of resistant strains infection. In this study, our data provide the association between antibiotic resistance of H. pylori and gastritis pattern, which indicate the higher risk of resistant strain infection if the patients with atrophic gastritis, PPI history and older age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.